BRITISH drugmaker GlaxoSmithKline today agreed to buy Aiolos Bio for up to US$1.4 billion (RM6.5 billion), with focus on an asthma medication still at the testing stage.  

The acquisition hands GSK access to AIO-001, a long-acting antibody which is ready to enter Phase II clinical development for the treatment of adults with asthma.